Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN Experiment.

Physical review letters·2025

Same author

Dark Matter Search Results from 4.2 Tonne-Years of Exposure of the LUX-ZEPLIN (LZ) Experiment.

Physical review letters·2025

Same author

First Dark Matter Search Results from the LUX-ZEPLIN (LZ) Experiment.

Physical review letters·2023

Same author

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.

Journal of virus eradication·2023

Same author

GlyT1 encephalopathy: Characterization of presumably disease causing GlyT1 mutations.

Neurochemistry international·2020

Same author

Heteroresistant Bacteria Detected by an Extended Raman-Based Antibiotic Susceptibility Test.

Analytical chemistry·2020

Search research articles

Related Experiment Video

Updated: May 17, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Everolimus improves experimental autoimmune uveoretinitis.

M Hennig¹, D Bauer, S Wasmuth

¹Ophtha-Lab, Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany. maren.hennig@uveitis-zentrum.de

Experimental Eye Research

|October 13, 2012

Summary

This summary is machine-generated.

Everolimus effectively treats experimental autoimmune uveoretinitis (EAU) by suppressing pathogenic immune responses and increasing regulatory T cells (Tregs). This immunosuppressive mechanism offers a novel therapeutic avenue for autoimmune eye diseases.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: May 17, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

Immunology
Ophthalmology
Pharmacology

Background:

Experimental autoimmune uveoretinitis (EAU) is an autoimmune disease model for human uveitis.
Understanding the immunomodulatory effects of drugs like everolimus is crucial for developing new treatments.

Purpose of the Study:

To analyze the efficacy and mechanism of action of everolimus in treating EAU.
To investigate everolimus's impact on antigen-specific immune responses, cytokine production, and regulatory T cells.

Main Methods:

EAU was induced in B10.RIII mice using immunization with hIRBPp161-180 peptide.
Everolimus was administered orally, and its effects were assessed through histopathological scoring, immune cell proliferation assays, cytokine analysis (ELISA, Bead Array), antibody testing, and flow cytometry for regulatory T cells (Tregs).

Main Results:

Everolimus significantly reduced uveitis severity and impaired delayed-type hypersensitivity (DTH) responses, humoral immunity, and splenocyte proliferation.
Treatment with everolimus suppressed intraocular and in vitro production of Th1 and Th17 cytokines.
Everolimus increased the number and suppressive capacity of splenic CD4+CD25+FoxP3+ regulatory T cells (Tregs).

Conclusions:

Everolimus demonstrates immunosuppressive effects in EAU by inhibiting pathogenic effector responses.
The induction of regulatory T cells (Tregs) is a key mechanism underlying everolimus's therapeutic action in EAU.